期刊文献+

第5代头孢菌素类抗生素的研究进展和市场动态 被引量:8

Research Progress and Market Trend of the Fifth Generation Cephalosporin Antibiotics
原文传递
导出
摘要 头孢菌素类抗生素具有抗菌活性强、抗菌谱广、耐β-内酰胺酶、耐酸碱、毒副作用小等优点,是治疗细菌感染性疾病的常用药,目前第5代已进入临床研究阶段。综述了第5代头孢菌素类抗生素的国内外研究进展,并对其市场进行了SWOT分析和展望,旨在为头孢菌素类抗生素的市场及临床应用的合理化发展提供参考。 Cephalosporin antibiotics have a variety of advantages, including strong antibacterial activity, wide antimicrobial spectrum, resistance to β-actamase, acid and alkali, as well as low toxicity. They have been commonly used for the treatment of bacterial infectious diseases. The fifth generation cephalosporin antibiotics both have entered the stage of clinical research. The research progress of fiRh generation eephalosporin antibiotics both at borne and abroad has been reviewed in this paper, and the Strengths Weakness Opportunity Threats (SWOT) analysis and the prospect of their market trend have been conducted, so as to provide references for the rational development of the market and clinical applications of cephalosporin antibiotics.
出处 《药学进展》 CAS 2014年第10期741-746,共6页 Progress in Pharmaceutical Sciences
关键词 头孢菌素类抗生素 MRSA 联合用药 市场动态 cephalosporin antibiotic MRSA drugs combination market trend
  • 相关文献

参考文献19

  • 1顾觉奋,戴君.新一代抗MRSA抗生素的临床研究进展[J].抗感染药学,2009,6(4):223-228. 被引量:11
  • 2王霞.抗菌药研发联手合作或成崧然[N].医药经济报,2012-06-25.
  • 3武英.全球抗生素市场概况分析[J].国外医药(抗生素分册),2012,33(3):119-124. 被引量:9
  • 4中国行业研究网.国外头孢菌素市场浅析[EB/OL].[EB/OL]. (2005-06-113)[2014-04-25]. http://www.chinairn.com/doc/70280/21157.html.
  • 5李艳平.国内外头孢菌素类药物研究开发新进展[J].黑龙江医药,2012,25(2):286-288. 被引量:9
  • 6苏丹,罗璨.第5代头孢菌素类药物研究进展[J].中国药房,2012,23(32):3057-3061. 被引量:6
  • 7Noel G J, Strauss R S, Amsler K, et al. Results of a double blind randomized trial of ceflobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria [J]. Antimicrob Agents Chemother, 2008, 52 (1): 37-44.
  • 8Davies T A, Flamm R K, Lynch A S. Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone [J]. lntJAntimicrob Agents, 2012, 39 (6): 534-538.
  • 9Kresken M, K6ber-lrrgang B, L/iffer J, et al. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time- kill methodology [J]. lnt J Antimicrob Agents, 2011, 38 (1): 70-75.
  • 10Kanafani Z A. Ceftaroline fosamil: drug profile and clinical data [J]. Future Microbiol, 201 I, 6 ( 1 ): 9 - 18.

二级参考文献61

共引文献31

同被引文献79

  • 1梅乐和,胡升,许静,姚善泾,郑晓冬.纳豆枯草杆菌的筛选和纳豆激酶发酵条件优化[J].浙江大学学报(工学版),2004,38(10):1355-1360. 被引量:42
  • 2傅德才,狄蕊,李彬.头孢菌素类抗生素的研究进展[J].河北师范大学学报(自然科学版),2006,30(6):693-697. 被引量:17
  • 3Livermore D M. Has the era of untreatable in fectionsarrived[J]. J Antimicrob Chemother, 2009,64(Suppl 1):i29-i36.
  • 4Falagas M E, Bliziotis I A. Pandrug-resistant Gram-negativebacteria: the dawn of the post-antibioric era[J]. Int JAntimicrob Agents, 2007, 29(6): 630-636.
  • 5Livermore D M, Woodford N. The p-lactamase threat inEnterobacteriaceae, Pseudomonas and Acinetobacter[i].Trends Microbiol, 2006, 14(9): 413-420.
  • 6Rice L B. Federal funding for the study of antimicrobialresistance in nosocomial pathogens: No ESKAPE[J]. JInfect Dis, 2008, 197(8): 1079-1081.
  • 7Policy I P. The 10X20 initiative: pursuing a globalcommitment to develop 10 new antibacterial drugs by2020[J]. Clin Infect Dis,2010, 50(15): 1081-1083.
  • 8Taubes G. The bacteria fight back[J]. Science, 2008,321(5894): 1294-1295.
  • 9Torres C. Up against the wall[J]. Nat Med, 2010,16(6): 628-631.
  • 10Silver L L. Challenges of antibacterial discovery[J]. ClinMicrobiol Rev, 2011, 24(1): 71-109.

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部